A5055043758- Hepatocellular Carcinoma Treatment and Prognosis
- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Renal cell carcinoma treatment
- Liver Disease and Transplantation
- Lung Cancer Treatments and Mutations
- Nanoplatforms for cancer theranostics
- Cancer Immunotherapy and Biomarkers
- Organ Transplantation Techniques and Outcomes
- CAR-T cell therapy research
- Cancer, Hypoxia, and Metabolism
- Colorectal Cancer Treatments and Studies
- Cancer Mechanisms and Therapy
- Liver Disease Diagnosis and Treatment
- Urinary Bladder and Prostate Research
- Tuberous Sclerosis Complex Research
- Urologic and reproductive health conditions
- Nuclear Materials and Properties
- Advanced Radiotherapy Techniques
- Abdominal Trauma and Injuries
- Angiogenesis and VEGF in Cancer
- Management of metastatic bone disease
- Maternal and fetal healthcare
- Toxin Mechanisms and Immunotoxins
- Liver physiology and pathology
US Biologic (United States)
2024
Salus (United States)
2024
Georgetown University
2014-2022
Georgetown University Medical Center
2018-2022
MedStar Georgetown University Hospital
2014-2020
The purpose of this retrospective study was to evaluate the efficacy incorporating trans-arterial radioembolization (TARE) with systemic chemotherapy in treatment liver-dominant metastatic pancreatic ductal adenocarcinoma, aim destroying liver metastases and improving patient outcomes. We retrospectively evaluated 16 patients adenocarcinoma who underwent TARE between February 2012 August 2015; 15 these also concurrent chemotherapy. Patient outcomes were assessed using Response Evaluation...
Objectives: Pressure-Enabled Drug Delivery (PEDD), a method using pressure to advance catheter-delivered drug distribution, can improve treatment for hepatocellular carcinoma (HCC) and liver metastases, but real-world evidence is limited. We compared baseline patient characteristics, clinical complexity, post-procedure healthcare resource utilization (HRUs) complications PEDD non-PEDD procedures.
PurposeTo test the hypothesis that Pressure-Enabled Drug Delivery (PEDD) would improve delivery of surrogate therapeutic glass microspheres (GMs) via hepatic artery infusion to liver tumors when compared with a conventional endhole microcatheter.Materials and MethodsThe study was conducted in transgenic pigs (Oncopigs) induced tumors. Tumors were infused intra-arterially fluorescently labeled GM. PEDD specialized device (TriNav; TriSalus Life Sciences, Westminster, Colorado) microcatheter...
Abstract The most commonly used preclinical models of hepatocellular carcinoma (HCC) are limited for use in testing intra‐arterial therapies such as transarterial chemoembolization and radioembolization. Issues encountered with the more animal include dissimilarity their disease development compared humans size vasculature which can make therapy difficult or impossible. Here we describe suitability woodchuck HCC model therapies. We techniques pre‐embolization imaging assessment using CT MRI,...
Trans-radial access offers several unique advantages and is being used more frequently for interventional radiology procedures. We report the use of trans-radial arterial to embolize a large bleeding angiomyolipoma in 30-year-old pregnant patient presenting first trimester. approach was chosen minimize effects radiation on fetus. Subsequent postprocedural pregnancy course uneventful with stability no further hemorrhage. This case highlights benefits embolotherapy gravid patients reduce risk exposure
Purpose To review the initial imaging responses after drug-eluting embolic trans-arterial chemoembolization (DEE-TACE) delivered with Surefire Infusion System ® for treatment of hepatocellular carcinoma (HCC). Methods Single center retrospective evaluation patients who underwent DEE-TACE HCC, SIS. Information was gathered from available medical records. Treatment response rates were assessed using modified Response Evaluation Criteria in Solid Tumors criteria. Assessment adverse events...
Patients with primary and secondary liver cancers generally have a poor prognosis limited potentially curative options. Liver-directed, intra-arterial therapies such as selective internal radiotherapy (SIRT) trans-arterial chemoembolization (TACE) are taking larger role in the management of these patients. The current standard therapy is for delivery SIRT or TACE particles through an end-hole microcatheter. Antireflux microcatheters (ARM) novel class designed to enhance therapies. These...
Abstract Background and Aims In patients with surgically unresectable early intermediate stage hepatocellular carcinoma (HCC), only liver transplant (LT) offers a cure. Locoregional therapies, such as transarterial chemoembolization (TACE), are widely used to bridge waiting for an LT or downstage tumors beyond Milan Criteria (MC). However, there no formal guidelines on the number of TACE procedures should receive. Our study explores extent which repeated might offer diminishing gains toward...
TPS358 Background: The anti–PD-L1 antibody ATEZO prevents PD-L1 from interacting with PD-1 and B7.1, thus reinvigorating antitumor T cell activity. Anti-VEGF BEV can increase dendritic maturation, enhance infiltration, reduce myeloid-derived suppressor cells regulatory T-cells in tumors. This combination has been FDA approved for first-line treatment of advanced HCC based on the IMbrave 150 study. On other hand, locoregional radiotherapy (e.g., Y90 TARE) enhances diversity intratumoral...
e15745 Background: Patients with chemotherapy-treated metastatic pancreatic cancer typically survive for 7 to 11 months. Liver metastases from the pancreas are common and can reduce survival. Radioembolization of these Y-90 resin microspheres (Y-90 resin) may tumor burden improve prognosis, but data limited. We report early a multicenter database patients adenocarcinoma treated resin. Methods: Retrospective patient, treatment, outcome were entered by each site (Georgetown, U Maryland)....
TPS773 Background: Treatment with Regorafenib (REGO) has shown significant clinical benefits in metastatic colorectal cancer (mCRC) patients (pts) as demonstrated the CORRECT and CONCUR trials. Results from both studies suggest that subgroups have differential responses. Further research to identify these through identification of molecular biomarkers is needed. Methods: Forty pts refractory mCRC are being enrolled this study. The primary objective prospectively tissue serum-based can...
461 Background: Hepatocellular carcinoma (HCC) is the sixth most common cancer and second leading cause of cancer-related death worldwide. Most HCCs develop in severely damaged liver. Methods: The effect multiple treatment options on liver function (LF) disease outcome patients (pts) with HCC (n = 185) were examined retrospectively. Pt tumor burden (using Barcelona clinic [BCLC] classification) LF (Child Pugh [CP]) assessed at time diagnosis then after treatment. Using Kaplan Meier log rank...
442 Background: Hepatocellular carcinoma (HCC) is the sixth most common cancer, and second leading cause of cancer-related death, worldwide. This reflects challenges facing HCC treatment. Methods: Patients (pts) with receiving TACE treatment (n = 96) were examined retrospectively for clinical outcome its possible predictors. The number treatments time elapsed between each assessed correlated overall survival (OS) using log rank test Kaplan Meier curves. T-stage, level differentiation,...
346 Background: There is a lack of data on the potential efficacy incorporation trans-arterial radioembolization (TARE) for metastatic pancreatic adenocarcinoma. We retrospectively evaluated TARE in management patients with liver dominant adenocarcinoma Methods: Sixteen were treated concurrent systemic therapy and liver-dominant from February, 2014 to August, 2015. Electronic chart review was performed this group assess response Results: Eleven male 5 female Yttrium-90 resin microspheres....
e22100 Background: The value of early phase clinical trials novel therapeutics is greatly enhanced through serial tumor biopsies to assess pharmacodynamic markers drug activity. However, the optimal biopsy and target characteristics have yet be defined for core needle biopsies. Methods: We analyzed obtained from patients enrolled in our trials. At time each 3-5 specimens were obtained, with at least one placed formalin embedded paraffin (FFPE). “Paired biopsies” those same patient on two...
TPS529 Background: Treatment of locally advanced pancreatic cancer (LAPC) remains a challenge, and novel therapy options for local treatment disease beyond systemic are needed. Recently published data intra-arterial delivery gemcitabine (IAG) control has shown this approach to be safe (J. Pancreatic Cancer 3(1) 58:65). Furthermore, in patients who have received prior radiation LAPC, there seems an effect on the microvasculature that enhances clinical efficacy IAG. TIGeR-PaC is randomized...
686 Background: Radioembolizaton with yttrium-90 (Y90) has been shown to decrease progression within the liver in patients unresectable metastatic colorectal cancer (CRC). Molecular profiling (MP) plays an important role providing precision based therapy for our patients. The purpose of this study was evaluate predictive associations between genetic mutations Y90 treated CRC pts and treatment outcomes. Methods: A retrospective chart review at GUMH conducted who underwent radioembolization...